SLSN Quote, Financials, Valuation and Earnings

Grove Collaborative Holdings, Inc. has a net margin of -7.67% compared to Solesence, Inc.'s net margin of -6.77%. Solesence, Inc.'s return on equity of 6.62% beat Grove Collaborative Holdings, Inc.'s return on equity of -151.59%.

Solesence, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Grove Collaborative Holdings, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 42.86%. Given that Grove Collaborative Holdings, Inc. has higher upside potential than Solesence, Inc., analysts believe Grove Collaborative Holdings, Inc. is more attractive than Solesence, Inc..

Solesence, Inc. has a beta of 1.083, which suggesting that the stock is 8.259% more volatile than S&P 500. In comparison Grove Collaborative Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Solesence, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grove Collaborative Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solesence, Inc. pays -- of its earnings as a dividend. Grove Collaborative Holdings, Inc. pays out -- of its earnings as a dividend.

Solesence, Inc. quarterly revenues are $14.6M, which are smaller than Grove Collaborative Holdings, Inc. quarterly revenues of $43.7M. Solesence, Inc.'s net income of -$1.1M is higher than Grove Collaborative Holdings, Inc.'s net income of -$3M. Notably, Solesence, Inc.'s price-to-earnings ratio is 105.71x while Grove Collaborative Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solesence, Inc. is 1.70x versus 0.30x for Grove Collaborative Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kenvue, Inc. has a net margin of -7.67% compared to Solesence, Inc.'s net margin of 10.58%. Solesence, Inc.'s return on equity of 6.62% beat Kenvue, Inc.'s return on equity of 13.85%.

Solesence, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kenvue, Inc. has an analysts' consensus of $19.33 which suggests that it could grow by 8.61%. Given that Kenvue, Inc. has higher upside potential than Solesence, Inc., analysts believe Kenvue, Inc. is more attractive than Solesence, Inc..

Solesence, Inc. has a beta of 1.083, which suggesting that the stock is 8.259% more volatile than S&P 500. In comparison Kenvue, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Solesence, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kenvue, Inc. offers a yield of 4.64% to investors and pays a quarterly dividend of $0.21 per share. Solesence, Inc. pays -- of its earnings as a dividend. Kenvue, Inc. pays out 150.5% of its earnings as a dividend.

Solesence, Inc. quarterly revenues are $14.6M, which are smaller than Kenvue, Inc. quarterly revenues of $3.8B. Solesence, Inc.'s net income of -$1.1M is lower than Kenvue, Inc.'s net income of $398M. Notably, Solesence, Inc.'s price-to-earnings ratio is 105.71x while Kenvue, Inc.'s PE ratio is 23.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solesence, Inc. is 1.70x versus 2.29x for Kenvue, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

The Beauty Health Co. has a net margin of -7.67% compared to Solesence, Inc.'s net margin of -15.61%. Solesence, Inc.'s return on equity of 6.62% beat The Beauty Health Co.'s return on equity of -19.76%.

Solesence, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand The Beauty Health Co. has an analysts' consensus of $1.96 which suggests that it could grow by 28%. Given that The Beauty Health Co. has higher upside potential than Solesence, Inc., analysts believe The Beauty Health Co. is more attractive than Solesence, Inc..

Solesence, Inc. has a beta of 1.083, which suggesting that the stock is 8.259% more volatile than S&P 500. In comparison The Beauty Health Co. has a beta of 1.162, suggesting its more volatile than the S&P 500 by 16.231%.

Solesence, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Beauty Health Co. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solesence, Inc. pays -- of its earnings as a dividend. The Beauty Health Co. pays out -- of its earnings as a dividend.

Solesence, Inc. quarterly revenues are $14.6M, which are smaller than The Beauty Health Co. quarterly revenues of $70.7M. Solesence, Inc.'s net income of -$1.1M is higher than The Beauty Health Co.'s net income of -$11M. Notably, Solesence, Inc.'s price-to-earnings ratio is 105.71x while The Beauty Health Co.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solesence, Inc. is 1.70x versus 0.65x for The Beauty Health Co.. Usually stocks with elevated PS ratios are considered overvalued.

Waldencast Plc has a net margin of -7.67% compared to Solesence, Inc.'s net margin of --. Solesence, Inc.'s return on equity of 6.62% beat Waldencast Plc's return on equity of -5.64%.

Solesence, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Waldencast Plc has an analysts' consensus of $3.08 which suggests that it could grow by 64.37%. Given that Waldencast Plc has higher upside potential than Solesence, Inc., analysts believe Waldencast Plc is more attractive than Solesence, Inc..

Solesence, Inc. has a beta of 1.083, which suggesting that the stock is 8.259% more volatile than S&P 500. In comparison Waldencast Plc has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Solesence, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Waldencast Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Solesence, Inc. pays -- of its earnings as a dividend. Waldencast Plc pays out -- of its earnings as a dividend.

Solesence, Inc. quarterly revenues are $14.6M, which are larger than Waldencast Plc quarterly revenues of --. Solesence, Inc.'s net income of -$1.1M is higher than Waldencast Plc's net income of --. Notably, Solesence, Inc.'s price-to-earnings ratio is 105.71x while Waldencast Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Solesence, Inc. is 1.70x versus 0.71x for Waldencast Plc. Usually stocks with elevated PS ratios are considered overvalued.